Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics I
- 4:30PM-6:00PM
-
Abstract Number: 948
Application of a Diagnostic Algorithm to Identify Inflammatory Myopathy in Systemic Sclerosis
- 4:30PM-6:00PM
-
Abstract Number: 945
Autoantibodies to the hPOP1 and Rpp25/38 Components of the Th/to Complex Identify a Subgroup of Systemic Sclerosis (SSc) Associated Interstitial Lung Disease (ILD) and Antibodies to hPOP1 Are Associated with Reduced Survival
- 4:30PM-6:00PM
-
Abstract Number: 946
Clinical and Serological Features of Systemic Sclerosis in a Multicenter African American Cohort: Analysis of the Genome Research in African American Scleroderma Patients Clinical Database
- 4:30PM-6:00PM
-
Abstract Number: 944
Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
- 4:30PM-6:00PM
-
Abstract Number: 947
Norway As a National Reference Population for Systemic Sclerosis; Preliminary Results from a Complete, Nationwide Cohort